Intuitive surgical EVP Mark Brosius sells $17,140 in stock

Intuitive Surgical's Executive Vice President and Chief Manufacturing and Supply Chain Officer, Mark Brosius, sold a total of $17,140 worth of company stock in two transactions during September 2026. The first sale involved 23 shares at $347.66 per share on September 10, 2026, while the second transaction comprised 25 shares at $365.79 each on September 11, 2026.

These sales were executed according to a pre-determined Rule 10b5-1 trading plan, which is scheduled to conclude on February 14, 2027. As a result of these transactions, Brosius currently owns 764 shares of Intuitive Surgical common stock. Despite the stock's current price of $369.15, which represents a 34.8% decrease year-to-date, the company's financial performance remains robust.

Intuitive Surgical's second-quarter sales surged by 19% to $2.89 billion, exceeding analysts' expectations. The company's various segments, including instruments and accessories (up 18% to $1.73 billion), systems (up 19% to $685 million), and services (up 21% to $472 million), all contributed to this growth. Additionally, earnings per share increased by 28% to $2.80, surpassing analyst forecasts by 12%.

In response to these developments, several financial analysts have revised their ratings and price targets for Intuitive Surgical. Oppenheimer upgraded the stock to "Outperform," setting a price target of $500, while UBS initiated coverage with a "Buy" rating and a similar target of $500. Conversely, Bernstein maintained an "Outperform" rating but reduced its price target to $685 due to concerns regarding U.S. growth prospects.

Piper Sandler, on the other hand, retained an "Overweight" rating with a $470 price target, expressing confidence in the company's future.